$370,000.00 in Sales Expected for G1 Therapeutics, Inc. (NASDAQ:GTHX) This Quarter

Equities analysts predict that G1 Therapeutics, Inc. (NASDAQ:GTHX) will announce $370,000.00 in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for G1 Therapeutics’ earnings, with the lowest sales estimate coming in at $100,000.00 and the highest estimate coming in at $590,000.00. The firm is expected to issue its next quarterly earnings results on Wednesday, May 5th.

On average, analysts expect that G1 Therapeutics will report full year sales of $18.60 million for the current financial year, with estimates ranging from $14.28 million to $22.40 million. For the next year, analysts forecast that the firm will report sales of $69.88 million, with estimates ranging from $59.53 million to $85.50 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for G1 Therapeutics.

G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings data on Wednesday, February 24th. The company reported ($0.67) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.88) by $0.21. The business had revenue of $16.55 million during the quarter, compared to analysts’ expectations of $14.00 million.

Several equities research analysts have recently commented on the company. Needham & Company LLC decreased their price target on G1 Therapeutics from $74.00 to $68.00 and set a “buy” rating on the stock in a research note on Wednesday, March 3rd. Zacks Investment Research lowered G1 Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 20th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $45.00.

In other G1 Therapeutics news, insider Rajesh Malik sold 15,000 shares of the business’s stock in a transaction on Tuesday, March 23rd. The stock was sold at an average price of $21.94, for a total value of $329,100.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark A. Velleca sold 10,000 shares of the business’s stock in a transaction on Thursday, February 18th. The shares were sold at an average price of $26.02, for a total value of $260,200.00. Following the completion of the transaction, the director now owns 52,040 shares of the company’s stock, valued at $1,354,080.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 61,040 shares of company stock worth $1,502,608. 14.49% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. State Street Corp increased its holdings in shares of G1 Therapeutics by 73.8% during the 3rd quarter. State Street Corp now owns 2,365,259 shares of the company’s stock worth $27,319,000 after buying an additional 1,004,346 shares during the last quarter. Nuveen Asset Management LLC increased its holdings in shares of G1 Therapeutics by 82.6% during the 4th quarter. Nuveen Asset Management LLC now owns 699,335 shares of the company’s stock worth $12,580,000 after buying an additional 316,336 shares during the last quarter. BlackRock Inc. increased its holdings in shares of G1 Therapeutics by 10.0% during the 4th quarter. BlackRock Inc. now owns 2,893,593 shares of the company’s stock worth $52,056,000 after buying an additional 262,986 shares during the last quarter. Voloridge Investment Management LLC increased its holdings in shares of G1 Therapeutics by 1,237.1% during the 4th quarter. Voloridge Investment Management LLC now owns 258,777 shares of the company’s stock worth $4,655,000 after buying an additional 239,423 shares during the last quarter. Finally, Great West Life Assurance Co. Can increased its holdings in shares of G1 Therapeutics by 5,130.7% during the 3rd quarter. Great West Life Assurance Co. Can now owns 119,102 shares of the company’s stock worth $881,000 after buying an additional 116,825 shares during the last quarter. Institutional investors own 77.89% of the company’s stock.

Shares of NASDAQ:GTHX traded up $0.41 during trading on Monday, hitting $25.45. 22,013 shares of the stock were exchanged, compared to its average volume of 1,601,808. The company has a fifty day moving average price of $23.26 and a two-hundred day moving average price of $18.77. The company has a market cap of $1.07 billion, a PE ratio of -8.63 and a beta of 2.44. The company has a current ratio of 7.45, a quick ratio of 7.45 and a debt-to-equity ratio of 0.10. G1 Therapeutics has a 12-month low of $10.81 and a 12-month high of $37.07.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.

Recommended Story: Gap Up Stocks

Get a free copy of the Zacks research report on G1 Therapeutics (GTHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.